Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) COO Sells $35,451.27 in Stock

Posted by on Apr 1st, 2023

Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Rating) COO Daniel Bensen sold 2,187 shares of the business’s stock in a transaction dated Wednesday, March 29th. The shares were sold at an average price of $16.21, for a total value of $35,451.27. Following the completion of the sale, the chief operating officer now directly owns 527,981 shares of the company’s stock, valued at $8,558,572.01. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Daniel Bensen also recently made the following trade(s):

  • On Monday, March 27th, Daniel Bensen sold 8,048 shares of Tyra Biosciences stock. The shares were sold at an average price of $16.00, for a total value of $128,768.00.
  • On Wednesday, March 22nd, Daniel Bensen sold 3,800 shares of Tyra Biosciences stock. The shares were sold at an average price of $16.00, for a total value of $60,800.00.

Tyra Biosciences Stock Performance

Shares of TYRA stock opened at $16.07 on Friday. Tyra Biosciences, Inc. has a 52-week low of $4.93 and a 52-week high of $16.86. The stock’s 50-day moving average price is $13.06 and its 200 day moving average price is $9.30.

Hedge Funds Weigh In On Tyra Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in TYRA. JPMorgan Chase & Co. lifted its stake in Tyra Biosciences by 47.8% in the 1st quarter. JPMorgan Chase & Co. now owns 228,482 shares of the company’s stock valued at $2,445,000 after buying an additional 73,903 shares in the last quarter. State Street Corp grew its stake in shares of Tyra Biosciences by 55.5% during the first quarter. State Street Corp now owns 203,680 shares of the company’s stock valued at $2,179,000 after acquiring an additional 72,670 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Tyra Biosciences by 1,020.1% during the first quarter. Bank of America Corp DE now owns 64,126 shares of the company’s stock worth $686,000 after purchasing an additional 58,401 shares during the last quarter. TCG Crossover Management LLC lifted its position in shares of Tyra Biosciences by 5.5% during the third quarter. TCG Crossover Management LLC now owns 945,707 shares of the company’s stock worth $8,313,000 after purchasing an additional 49,289 shares during the last quarter. Finally, Woodline Partners LP lifted its holdings in Tyra Biosciences by 8.6% in the second quarter. Woodline Partners LP now owns 289,172 shares of the company’s stock worth $2,068,000 after acquiring an additional 23,011 shares during the last quarter. Institutional investors and hedge funds own 84.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on TYRA shares. Oppenheimer boosted their price target on Tyra Biosciences from $17.00 to $25.00 in a research report on Wednesday, March 1st. HC Wainwright restated a “buy” rating and issued a $17.00 price target on shares of Tyra Biosciences in a research report on Thursday, March 23rd.

About Tyra Biosciences

(Get Rating)

Tyra Biosciences, Inc, a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.

See Also

Insider Buying and Selling by Quarter for Tyra Biosciences (NASDAQ:TYRA)

Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.